Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an announcement.
CR Double-Crane, a subsidiary of China Resources Pharmaceutical Group, reported a slight increase in total assets and net assets for the first half of 2025, despite a decrease in revenue and net profit compared to the previous year. The financial results indicate a challenging period with a decline in net profit and cash flow from operating activities, reflecting the company’s need to address operational efficiencies and market conditions.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. It holds a significant stake in CR Double-Crane, a company listed on the Shanghai Stock Exchange, which is involved in the pharmaceutical sector in China.
Average Trading Volume: 11,891,732
Technical Sentiment Signal: Sell
Current Market Cap: HK$33.05B
For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.